TABLE 2.
Associations of GGH expression a levels with clinicopathological characteristic according to logistic regression analysis.
| Characteristics | Total (N) | Odds ratio (OR) | p-value |
|---|---|---|---|
| Clinical stage (Stage II & Stage III & Stage IV vs. Stage I) | 543 | 1.90 (1.34–2.71) | <0.001 |
| Histologic grade (G3 vs. G1 & G2) | 532 | 3.00 (2.10–4.32) | <0.001 |
| Residual tumor (R1 & R2 vs. R0) | 410 | 1.32 (0.67–2.61) | 0.42 |
| Tumor invasion (%) (≥50 vs. <50) | 470 | 1.23 (0.85–1.77) | 0.274 |
| Primary therapy outcome (CR vs. PD & SD & PR) | 474 | 0.55 (0.28–1.08) | 0.086 |
| Histological type (Serous vs. Endometrioid) | 521 | 1.61 (1.06–2.47) | 0.026 |
| TP53 status (Mutant vs. Wild-type) | 526 | 1.86 (1.30–2.67) | <0.001 |
| Surgical approach (Minimally Invasive vs. Open) | 521 | 1.75 (1.23–2.51) | 0.002 |
| Menopause status (Post vs. Pre and Peri) | 497 | 1.31 (0.74–2.36) | 0.356 |
| Radiation therapy (No vs. Yes) | 518 | 0.94 (0.67–1.33) | 0.74 |
| Hormones therapy (No vs. Yes) | 339 | 1.00 (0.53–1.89) | 0.991 |
| Diabetes (No vs. Yes) | 442 | 0.99 (0.65–1.50) | 0.945 |
| Race (Asian and African American vs. White) | 498 | 1.62 (1.08–2.45) | 0.021 |
| Age (≤60 vs. >60) | 540 | 0.87 (0.62–1.23) | 0.438 |
| Weight (≤80 vs. >80) | 521 | 1.89 (1.33–2.68) | <0.001 |
| Height (≤160 vs. >160) | 514 | 1.15 (0.81–1.63) | 0.423 |
| BMI (≤30 vs. >30) | 512 | 1.69 (1.18–2.41) | 0.004 |
| TP53 status (Mutant vs. Wild-type) | 526 | 1.86 (1.30–2.67) | <0.001 |
a
Categorical dependent variable, greater, or less than the median expression level.